Derm News: 2007.8(6)

Alefacept in corticosteroid refractory graft versus host disease: Early Results indicate promising activity

Journal of Dermatological Treatment, Volume 18, Issue 1 2007, pages 13-18
Amir A. Toor; Patrick J. Stiff; Brian J. Nickoloff; Tulio Rodriguez; Jared L. Klein; Kenneth B. Gordon
ABSTRACT

Steroid refractory graft versus host disease (GVHD) presents a significant therapeutic challenge due to the limited efficacy and safety of second-line treatments. Three patients with extensively pretreated, refractory GVHD were treated with a targeted anti-T-cell agent, alefacept, and demonstrated rapid and clinically significant improvement in their GVHD, facilitating tapering of corticosteroids. The pathological and immunohistochemical findings of GVHD also improved, validating our clinical impression. These preliminary findings indicate that alefacept may have beneficial activity in GVHD warranting further study.

    Back to Current Volume:   Dermatology News 2007.8

The Derm News service provided by the Editorial Consultants of Skin Therapy Letter^© and its founding editor Dr. Stuart Maddin.